ACADIA Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 70 to 93.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating in the early stages of their moves.
Is ACADIA Pharmaceuticals Stock A Buy?
ACADIA Pharmaceuticals stock is now considered extended and out of buy range after clearing a 20.68 buy point in a first-stage cup without handle. See if the biotech stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Earnings growth dropped last quarter from 207% to 10%. But revenue moved higher, from 12% to 19%.
ACADIA Pharmaceuticals stock holds the No. 4 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis is the top-ranked stock within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
